Summary Electron affinity as measured by the one-electron reduction potential, E7,, is the major factor influencing radiosensitizing efficiency in vitro. RSU 1069 has an electron affinity (E1 -398 mV) similar to misonidazole; however, the ability of this compound to sensitize hypoxic cells is considerably greater thdn that of misonidazole, e.g. 0.2mM RSU 1069 gives an enhancement ratio of 2.2 compared to 1.5 for the same concentration of misonidazole. Radiosensitization studies with the MT tumour in vivo also showed RSU 1069 to be a more efficient sensitizer than misonidazole. An administered dose of only 0.08 mg g1 RSU 1069 yielded an enhancement of 1.8 to 1.9 using tumour cell survival and tumour cure as end-points.
Many electron affinic compounds can act as hypoxic cell radiosensitizers in experimental systems. One, misonidazole (MISO), has undergone considerable clinical evaluation but it is now clear that the neurotoxic properties of this drug will seriously limit its application. This is because the maximum clinical doses that can be achieved fall well short of those required for maximum sensitizing effectiveness.
In vitro studies have shown that electron affinity is generally the predominant factor which determined both the cytotoxic and radiation sensitizing efficiencies of hypoxia-mediated drugs (Adams et al., 1979a (Adams et al., , b, 1980a . However, there are some exceptions; in particular a number of compounds which show sensitizing efficiency much greater than would be predicted from their electron affinities. One such compound is the aziridinyl dinitrobenzene, CB 1954, synthesized originally as a cytotoxic agent (Cobb et al., 1969) and shown to have both alkylating and anti-metabolite properties (Connors & Malzack, 1971; Connors et al., 1972) . CB 1954 has an electron affinity similar to that of MISO but its ability to sensitize hypoxic cells to radiation is greater than that of MISO both in vitro and in vivo (Chapman et al., 1979; Stratford et al., 1981; Stratford, 1982) .
The compound 2-phenyl-4(5)-amino-5(4)-carboxamide (phenyl AIC) is known to protect against the cytotoxic effects of CB 1954 (Hickman & Melzack, 1975) . It has been shown that this compound, when present during irradiation, also reduces the efficiency of CB 1954 as a radiosensitizer to the level which would be predicted from its electron affinity (Stratford et al., 1981) . It was proposed, therefore, that the additional sensitization normally seen with CB 1954 might be associated with its cytotoxic activity.
We have subsequently included an aziridine group in a 2-nitroimidazole. The compound synthesized is RSU 1069 (NSC 347503, 1(2-nitro-1-imidazolyl)-3-aziridino-2-propanol) and its structure is given in figure 2. This agent shows considerably greater activity than MISO both in vitro and in vivo. This paper describes studies on radiosensitization by RSU 1069 and on its ability to act as a powerful potentiator of the anti-tumour action of melphalan.
Materials and methods

Compounds
The compound RSU 1069 was synthesized from azomycin in a similar manner to that described for other (2-nitro-1-imidazolyl)propanolamines (Smithen et al., 1980) 
Chemical properties
One-electron reduction potential, E', and the octanol: water partition coefficients, P, were measured as described previously (Adams et al., 1976) . The pKa of RSU 1069 was measured in aqueous media at room temperature using standard spectrophotometric methods.
Biological studies
Sensitizing efficiencies in vitro were obtained from changes in slopes of the linear portions of the radiation survival curves for hypoxic Chinese hamster V79 cells irradiated in the presence of various concentrations of RSU 1069.
Radiosensitization in vivo was measured using the anaplastic MT tumour implanted s.c. over the sacral region of the backs of female WHT/Cbi mice. When the tumours reached 5-6 mm in diameter, the unanaesthetised mice were dosed i.p. with RSU 1069 in saline, and locally irradiated with 230 kV X-rays (Sheldon & Hill, 1977a) . Tumour response was determined either by an in vitro soft agar clonogenic assay (Sheldon et al., 1982) or by the probability of local tumour control at 80 days (Sheldon & Hill, 1977b) . The soft agar clonogenic assay was also used in the chemopotentiation studies, where male mice bearing the MT tumour were treated i.p. with 5mg kg-1 melphalan. The in vitro assay for tumour response was always carried out 18 h after radiation and/or drug treatment.
Results
Radiosensitization in vitro Enhancement ratios were determined for radiation sensitization of hypoxic Chinese hamster cells in vitro by RSU 1069 using previously described protocols (Adams et al., 1976 (Adams et al., , 1979a (Adams et al., , 1980a . At the maximum concentration tested, RSU 1069 reduced plating efficiency of unirradiated cells by no more than 20% after a 2 h contact time in hypoxia at room temperature. Full hypoxic survival curves were obtained for a range of concentrations of RSU 1069. Some examples are shown in Figure  1 . At these concentrations RSU 1069 greatly increases the radiation response of hypoxic cells. In contrast, cells irradiated in air are not sensitized by this compound. Enhancement ratios for some concentrations were obtained from a single survival point (usually between 2 x 10-2 and 10-1) obtained by appropriate choice of radiation dose and by assuming an unchanged extrapolation number. Figure 2 shows the concentration dependence of the enhancement ratios for RSU 1069. The ratios for hypoxic cells irradiated in the presence of MISO (dashed line in Figure 2 ) were similar to those reported previously for this cell line (Adams et al., 1976 Radiosensitization It is known that, due to pharmacokinetic considerations, the time at which a sensitizer is administered to tumour-bearing mice prior to irradiation can greatly influence the observed radiation response (Sheldon & Hill, 1977b; McNally et al., 1978; Brown & Yu, 1980) . Therefore in initial experiments RSU 1069 was given i.p. to tumour-bearing mice at various times before an X-ray dose of 17 Gy. The response of the MT tumour to radiation + 0.08 mgg-1 RSU 1069 assessed by a clonogenic assay technique is shown in Figure 3 . Irradiation with a dose of 17 Gy alone only reduces tumour cell survival to 2 x 10-2. This is in line with previous data indicating that this tumour contains radiationresistant hypoxic cells. The decrease in cell survival due to sensitization is dependent upon the interval between drug administration and irradiation. Maximum sensitization appears to occur when the drug is given no earlier than 90 min before commencement of irradiation. For this time range survival is decreased to around 3 x 10-4. When RSU 1069 is given without irradiation, tumour cell survival is reduced to 0.5. Taking this into account, the maximum sensitization for this drug dose corresponds to an enhancement ratio of 1.8. This level of radiosensitization with MISO, in this tumour system, requires at least a 15-fold higher dose (Adams et al., 1984) . The sensitization efficiency of RSU 1069 was also measured in vivo by the TCD50 method. A single dose of 0.08mg g-1 was administered 90 min before the mice were given a range of doses of Xirradiation in order to assess the probability of local control of the MT tumour at 80 days. Data are shown in Figure 4 . In the absence of drug, 68Gy were required to achieve a 50% probability of tumour control (TCD50). In the drug-tested mice, the value of the TCD50 was reduced to 35 Gy.
This corresponds to an enhancement ratio of 1.9, and is consistent with the ER obtained from the clonogenic assay. 
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L MT tumour implanted intramuscularly (Sheldon et al., 1982) . This study showed that the compound Ro 03-8799 produced the greatest potentiation. We have compared the chemopotentiating properties of RSU 1069 with Ro 03-8799 using the clonogenic assay endpoint for subcutaneous tumours. Figure 5 shows the tumour cell response when the nitroimidazoles were given to mice before or after 5mg kg-melphalan. Melphalan alone reduces survival to 5 x 10-2 and the nitroimidazoles alone reduce survival by no more than 50%. However, the combination of the nitroimidazole with melphalan can cause a large increase in cell killing. The amount of potentiation is dependent upon the timing and sequencing of the drug combination. For Ro 03-8799 the optimum time is 30 min. Before melphalan, whereas for RSU 1069 it is 60 min. A dose of 0.72mg g-1 Ro 03-8799 with melphalan produced a maximum reduction in cell survival of 10-3, whereas a 10-fold lower dose of RSU 1069 caused a further 10-fold decrease in cell survival. These survival levels correspond to enhancement ratios of 2.3 for Ro 03-8799 and 3.0 for RSU 1069. 
Discussion
Some compounds (Desmethylmisonidazole, SR 2508 and Ro 03-8799) have been or are being considered as successors to misonidazole for clinical use. Desmethylmisonidazole and SR 2508 have similar sensitizing efficiencies to MISO both in vitro and in vivo. They were chosen on the basis of pharmacokinetic considerations suggesting the drugs would be less neurotoxic (Dische et al., 1980; Brown et al., 1981) . Ro 03-8799 showed greater sensitizing efficiency than MISO in vitro, but this was not reflected in vivo, where levels of sensitization were obtained which were no greater than would be expected from a similar administered dose of MISO (Williams et al., 1982) . However, the neurotoxicity of Ro 03-8799 was lower than MISO in baboons, (Eichler & Jackson personal communication, in Saunders et al., 1982) .
The compound RSU 1069 shows substantially greater radiosensitizing efficiency than MISO both in vitro and in vivo. This is the first nitroimidazole shown to be substantially more efficient than MISO in vivo. It warrants further evaluation in other tumour systems using both single and multi-fraction radiation regimes. It should be pointed out, that RSU 1069 is more toxic than MISO as measured by acute LD50 values in WHT/Cbi female mice where the respective LD50's are 0.15 mg g -1 and 1.8mg g-1. However, it would be premature at this stage to make any conclusions regarding relative therapeutic ratios without more detailed toxicological evaluation.
There is currently considerable interest in the use of MISO and other nitroimidazoles as potentiators of alkylating agents in vivo (Rose et al., 1980; Clement et al., 1980 Tannock, 1980a Law et al., 1981; Martin et al., 1981; Siemann, 1981; Mulcahy et al., 1981; Stephens et al., 1981; Twentyman, 1981) . Most of these combination studies have been concerned with MISO. Recently it has been shown that other nitro compounds can show potentiating activity considerably greater than MISO (Workman & Twentyman, 1982; Sheldon et al., 1982) . In one of these studies (Sheldon et al., 1982) Appendix RSU 1069 gave satisfactory elemental and mass spectural analyses. 1H.n.m.r. spectra were recorded in CDC13 relative to 2,2-dimethyl-2-silopentane-5-sulphonate as internal standard. Spin multiplicities are indicated by the symbols s(singlet), m (multiplet). Infrared spectra were recorded in nujol.
1-(2,3-epoxypropyl)-2-nitroimidazole (RSU 1062) was prepared using the method described by Beaman et al. (1967) . RSU 1062 was mixed with a twice molar excess of aziridine in methanol and heated under reflux for one hour. The solvent was removed under reduced pressure and the residue recrystallised from ethanol to give RSU 1069, mp 119-121°C, as a pale yellow crystalline solid (yield 56%). I.R.v(cm-'): 3160, 3120, 3080, 1530, 1500, 1483, 1290, 1262, 1157, 1140, 1007, 920, 887, 848, 836, 787, 775, 650 
